Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 20/20 | 1.00 |
| ▸ | CYP21A2 | P08686 | 20/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.80 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.80 |
| ▸ | CYP7A1 | P22680 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16608216 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL16600117 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL16599723 | 0.94 | CYP17A1 (0.89) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL16599720 | 0.94 | CYP17A1 (0.89) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL16608555 | 0.94 | CYP17A1 (0.89) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL16599844 | 0.93 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL16599848 | 0.93 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL16608506 | 0.93 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL16599852 | 0.92 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL16608386 | 0.92 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244436-A1 | NOVEL FUNCTIONALIZED 5-(PHENOXYMETHYL)-1,3-DIOXANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE | CORTENDO AB (PUBL) | 2016-08-25 | — | — | US | claimed |
| EP-3049084-A1 | NOVEL FUNCTIONALIZED 5-(PHENOXYMETHYL)-1,3-DIOXANE ANALOGS EXHIBITNG CYTOCHROME P450 INHIBITION | Cortendo AB (publ) (US) | 2016-08-03 | — | — | EP | claimed |
| WO-2015048311-A1 | NOVEL FUNCTIONALIZED 5-(PHENOXYMETHYL)-1,3-DIOXANE ANALOGS EXHIBITNG CYTOCHROME P450 INHIBITION | CORTENDO AB (PUBL) (US) | 2015-04-02 | — | — | WO | claimed |
| US-20160244436-A1 | NOVEL FUNCTIONALIZED 5-(PHENOXYMETHYL)-1,3-DIOXANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE | CORTENDO AB (PUBL) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244436-A1 | NOVEL FUNCTIONALIZED 5-(PHENOXYMETHYL)-1,3-DIOXANE ANALOGS EXHIBITING CYTOCHROME P450 INHIBITION AND THEIR METHOD OF USE | CYP11B1, CYP11B2, CYP21A2 | CYP17A1 4/4885CYP21A2 3/4885CYP11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.